{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:06:20Z","timestamp":1785456380681,"version":"3.56.0"},"reference-count":27,"publisher":"Walter de Gruyter GmbH","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpm-2016-0101_s_999_w2aab3b7b2b1b6b1aab1c17b1Aa\">\n                  <jats:title id=\"d1389240e4473_w2aab3b7b2b1b6b1aab1c17b1aAa\">Aim:<\/jats:title>\n                  <jats:p>The aim of this study was to evaluate the predictive value of \u03b1-fetoprotein in maternal serum (MS-AFP) as a marker for diverse pregnancy outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpm-2016-0101_s_998_w2aab3b7b2b1b6b1aab1c17b2Aa\">\n                  <jats:title id=\"d1389240e4481_w2aab3b7b2b1b6b1aab1c17b2aAa\">Methods:<\/jats:title>\n                  <jats:p>The study was based on pregnancy and delivery data from 5520 women between 1999 and 2014 at University Hospital of Zurich (UHZ). Inclusion criteria: both MS-AFP and pregnancy outcome were known for the same pregnancy. Pregnancy outcomes and characteristics such as fetal malformation, intrauterine fetal death (IUFD) and intrauterine growth retardation as well as maternal age, weight before pregnancy, gestational age (GA) at delivery, newborn weight, length and head circumference were analyzed with respect to the MS-AFP value. MS-AFP value was categorized into three groups: elevated MS-AFP&gt;2.5 multiples of the median (MoM), normal 0.5\u20132.49 MoM and decreased &lt;0.5 MoM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpm-2016-0101_s_997_w2aab3b7b2b1b6b1aab1c17b3Aa\">\n                  <jats:title id=\"d1389240e4489_w2aab3b7b2b1b6b1aab1c17b3aAa\">Results:<\/jats:title>\n                  <jats:p>Newborn weight (g) and length (cm) were significantly lower in the elevated MS-AFP (P&lt;0.001) group, and infants had 1 week lower GA at delivery (P&lt;0.05). In the group of elevated MS-AFP (n=46), 26.1% of pregnancies were significantly related to adverse pregnancy outcomes, such as fetal malformations, fetuses small for gestational age (SGA) and IUFD. Adverse pregnancy outcomes of 5.6% were registered in the group of normal MS-AFP and 7.3% in the group of low MS-AFP (P&lt;0.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpm-2016-0101_s_996_w2aab3b7b2b1b6b1aab1c17b4Aa\">\n                  <jats:title id=\"d1389240e4497_w2aab3b7b2b1b6b1aab1c17b4aAa\">Conclusion:<\/jats:title>\n                  <jats:p>MS-AFP level in the second trimester is still an important indicator of fetal surface malformations; however, ultrasound still outweighs as a screening method. Nevertheless, pregnant women with elevated MS-AFP values and with no sonographically detected fetal malformations should additionally receive the third trimester ultrasound examination to exclude other possible complications of pregnancy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpm-2016-0101","type":"journal-article","created":{"date-parts":[[2016,10,23]],"date-time":"2016-10-23T10:01:31Z","timestamp":1477216891000},"page":"817-820","source":"Crossref","is-referenced-by-count":15,"title":["Pregnancy outcomes regarding maternal serum AFP value in second trimester screening"],"prefix":"10.1515","volume":"45","author":[{"given":"Karolina","family":"Bartkute","sequence":"first","affiliation":[{"name":"Department of Obstetrics , University Hospital of Zurich , Z\u00fcrich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Balsyte","sequence":"additional","affiliation":[{"name":"Department of Obstetrics , University Hospital of Zurich , Z\u00fcrich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Wisser","sequence":"additional","affiliation":[{"name":"Department of Obstetrics , University Hospital of Zurich , Z\u00fcrich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juozas","family":"Kurmanavicius","sequence":"additional","affiliation":[{"name":"Department of Obstetrics , University Hospital of Zurich , Z\u00fcrich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2016,10,24]]},"reference":[{"key":"2023040100153360800_j_jpm-2016-0101_ref_001_w2aab3b7b2b1b6b1ab1b5b1Aa","doi-asserted-by":"crossref","unstructured":"Canick JA, Kellner LH, Bombard AT. Prenatal screening for open neural tube defects. Clin Lab Med. 2003;23:385\u201394.1284845010.1016\/S0272-2712(03)00032-5","DOI":"10.1016\/S0272-2712(03)00032-5"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_002_w2aab3b7b2b1b6b1ab1b5b2Aa","doi-asserted-by":"crossref","unstructured":"David Gitlin MB. Serum a-fetoprotein, albumin, and yG-globulin in the human conceptus. J Clin Invest. 1966;45:1826\u201338.10.1172\/JCI105486","DOI":"10.1172\/JCI105486"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_003_w2aab3b7b2b1b6b1ab1b5b3Aa","doi-asserted-by":"crossref","unstructured":"Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med (Maywood). 2001;226:377\u2013408.1139316710.1177\/153537020122600503","DOI":"10.1177\/153537020122600503"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_004_w2aab3b7b2b1b6b1ab1b5b4Aa","unstructured":"Gitlin D, Perricelli A, Gitlin GM. Synthesis of -fetoprotein by liver, yolk sac, and gastrointestinal tract of the human concept. Cancer Res. 1972;35:979\u201382."},{"key":"2023040100153360800_j_jpm-2016-0101_ref_005_w2aab3b7b2b1b6b1ab1b5b5Aa","doi-asserted-by":"crossref","unstructured":"Mizejewski GJ. Levels of alpha-fetoprotein during pregnancy and early infancy in normal and disease states. Obstet Gynecol Surv. 2003;58:804\u201326.10.1097\/01.OGX.0000099770.97668.1814668662","DOI":"10.1097\/01.OGX.0000099770.97668.18"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_006_w2aab3b7b2b1b6b1ab1b5b6Aa","doi-asserted-by":"crossref","unstructured":"Mizejewski GJ. Physiology of alpha-fetoprotein as a biomarker for perinatal distress: relevance to adverse pregnancy outcome. Exp Biol Med (Maywood). 2007;232:993\u20131004.10.3181\/0612-MR-29117720945","DOI":"10.3181\/0612-MR-291"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_007_w2aab3b7b2b1b6b1ab1b5b7Aa","doi-asserted-by":"crossref","unstructured":"Christensen RL, Rea MR, Kessler G, Crane JP, Valdes R Jr. Implementation of a screening program for diagnosing open neural tube defects: selection, evaluation, and utilization of alpha-fetoprotein methodology. Clin Chem. 1986;32:1812\u20137.2428543","DOI":"10.1093\/clinchem\/32.10.1812"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_008_w2aab3b7b2b1b6b1ab1b5b8Aa","doi-asserted-by":"crossref","unstructured":"Bredaki FE, Sciorio C, Wright A, Wright D, Nicolaides KH. Serum alpha-fetoprotein in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015;46:34\u201341.2565276910.1002\/uog.14809","DOI":"10.1002\/uog.14809"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_009_w2aab3b7b2b1b6b1ab1b5b9Aa","doi-asserted-by":"crossref","unstructured":"Bredaki FE, Wright D, Akolekar R, Cruz G, Nicolaides KH. Maternal serum alpha-fetoprotein in normal pregnancy at 11\u201313 weeks\u2019 gestation. Fetal Diagn Ther. 2011;30:274\u20139.2215638610.1159\/000330200","DOI":"10.1159\/000330200"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_010_w2aab3b7b2b1b6b1ab1b5c10Aa","doi-asserted-by":"crossref","unstructured":"Crandall BF, Robinson L, Grau P. Risks associated with an elevated maternal serum a-fetoprotein level. Am J Obstet Gynecol. 1991;165:581\u20136.10.1016\/0002-9378(91)90289-4","DOI":"10.1016\/0002-9378(91)90289-4"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_011_w2aab3b7b2b1b6b1ab1b5c11Aa","doi-asserted-by":"crossref","unstructured":"Roig MD, Sabri\u00e0 J, Valls C, Borr\u00e0s M, Mir\u00f3 E, Ponce J, et al. The use of biochemical markers in prenatal diagnosis of intrauterine growth retardation: insulin-like growth factor I, Leptin, and alpha-fetoprotein. Eur J Obstet Gynecol Reprod Biol. 2005;120:27\u201332.1586608210.1016\/j.ejogrb.2004.07.028","DOI":"10.1016\/j.ejogrb.2004.07.028"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_012_w2aab3b7b2b1b6b1ab1b5c12Aa","doi-asserted-by":"crossref","unstructured":"Audibert F, Benchimol Y, Benattar C, Champagne C, Frydman R, et al. Prediction of preeclampsia or intrauterine growth restriction by second trimester serum screening and uterine Doppler velocimetry. Fetal Diagn Ther. 2005;20:48\u201353.1560846010.1159\/000081369","DOI":"10.1159\/000081369"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_013_w2aab3b7b2b1b6b1ab1b5c13Aa","doi-asserted-by":"crossref","unstructured":"Beta J, Bredaki FE, Rodriguez Calvo J, Akolekar R, Nicolaides KH. Maternal serum alpha-fetoprotein at 11\u201313 weeks\u2019 gestation in spontaneous early preterm delivery. Fetal Diagn Ther. 2011;30:88\u201393.2141197710.1159\/000324352","DOI":"10.1159\/000324352"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_014_w2aab3b7b2b1b6b1ab1b5c14Aa","doi-asserted-by":"crossref","unstructured":"Bredaki FE, Mataliotakis M, Wright A, Wright D, Nicolaides KH, et al. Maternal serum alpha fetoprotein at 12, 22, 32 weeks\u2019 gestation in screening for preeclampsia. Ultrasound Obstet Gynecol. 2016;47:466\u201371.10.1002\/uog.1581826582719","DOI":"10.1002\/uog.15818"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_015_w2aab3b7b2b1b6b1ab1b5c15Aa","doi-asserted-by":"crossref","unstructured":"Androutsopoulos G, Gkogkos P, Decavalas G. Mid-trimester maternal serum HCG and alpha fetal protein levels: clinical significance and prediction of adverse pregnancy outcome. Int J Endocrinol Metab. 2013;11:102\u20136.23825981","DOI":"10.5812\/ijem.5014"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_016_w2aab3b7b2b1b6b1ab1b5c16Aa","doi-asserted-by":"crossref","unstructured":"Tancr\u00e8de S, Bujold E, Gigu\u00e8re Y, Renald MH, Girouard J, Forest JC. Mid-trimester maternal serum AFP and hCG as markers of preterm and term adverse pregnancy outcomes. J Obstet Gynaecol Can. 2015;37:111\u20136.2576794210.1016\/S1701-2163(15)30331-5","DOI":"10.1016\/S1701-2163(15)30331-5"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_017_w2aab3b7b2b1b6b1ab1b5c17Aa","doi-asserted-by":"crossref","unstructured":"Wei Yuan LC. Andres Lopez Bernal, Is elevated maternal serum alpha-fetoprotein in the second trimester of pregnancy associated with increased preterm birth risk? A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2009;145:57\u201364.10.1016\/j.ejogrb.2009.04.017","DOI":"10.1016\/j.ejogrb.2009.04.017"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_018_w2aab3b7b2b1b6b1ab1b5c18Aa","doi-asserted-by":"crossref","unstructured":"Roman A, Desai N, Krantz D, Liu HP, Rosner J, Vohra N, et al. Maternal serum analytes as predictors of IUGR with different degrees of placental vascular dysfunction. Prenat Diagn. 2014;34:692\u20138.24677013","DOI":"10.1002\/pd.4369"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_019_w2aab3b7b2b1b6b1ab1b5c19Aa","doi-asserted-by":"crossref","unstructured":"Wilson RD; SOGC Genetics Committee, Wilson RD, Audibert F, Brock JA, Campagnolo C, Carroll J, et al. Prenatal screening, diagnosis, and pregnancy management of fetal neural tube defects. J Obstet Gynaecol Can. 2014;36:927\u201339.10.1016\/S1701-2163(15)30444-825375307","DOI":"10.1016\/S1701-2163(15)30444-8"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_020_w2aab3b7b2b1b6b1ab1b5c20Aa","unstructured":"National Institute for Clinical Excellence. Antenatal care for uncomplicated pregnancies. NICE clinical guidelines. Updated edition. London, 2008."},{"key":"2023040100153360800_j_jpm-2016-0101_ref_021_w2aab3b7b2b1b6b1ab1b5c21Aa","doi-asserted-by":"crossref","unstructured":"Driscoll DA, Gross SJ. Screening for fetal aneuploidy and neural tube defects. Genet Med. 2009;11:818\u201321.10.1097\/GIM.0b013e3181bb267b19915395","DOI":"10.1097\/GIM.0b013e3181bb267b"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_022_w2aab3b7b2b1b6b1ab1b5c22Aa","doi-asserted-by":"crossref","unstructured":"Yaron Y, Cherry M, Kramer RL, O\u2019Brien JE, Hallak M, Johnson MP. Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol. 1999;181:968\u201374.1052176310.1016\/S0002-9378(99)70334-0","DOI":"10.1016\/S0002-9378(99)70334-0"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_023_w2aab3b7b2b1b6b1ab1b5c23Aa","doi-asserted-by":"crossref","unstructured":"Poon LC, Lesmes C, Gallo DM, Akolekar R, Nicolaides KH. Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 19\u201324 weeks. Ultrasound Obstet Gynecol. 2015;46:437\u201345.2598829310.1002\/uog.14904","DOI":"10.1002\/uog.14904"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_024_w2aab3b7b2b1b6b1ab1b5c24Aa","doi-asserted-by":"crossref","unstructured":"Lesmes C, Gallo DM, Gonzalez R, Poon LC, Nicolaides KH. Prediction of small-for-gestational-age neonates: screening by maternal serum biochemical markers at 19\u201324 weeks. Ultrasound Obstet Gynecol. 2015;46:341\u20139.2596996310.1002\/uog.14899","DOI":"10.1002\/uog.14899"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_025_w2aab3b7b2b1b6b1ab1b5c25Aa","doi-asserted-by":"crossref","unstructured":"Bartha JL, Illanes S, Gonz\u00e1lez-Bugatto F, Abdel-Fattah SA, Mizejewski GJ, Soothill PW. Maternal serum transformed alpha-fetoprotein levels in women with intrauterine growth retardation. Fetal Diagn Ther. 2007;22:294\u20138.1736108310.1159\/000100794","DOI":"10.1159\/000100794"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_026_w2aab3b7b2b1b6b1ab1b5c26Aa","doi-asserted-by":"crossref","unstructured":"Sharony R, Dayan D, Kidron D, Manor M, Berkovitz A, Biron-Shental T, et al. Is the ratio of maternal serum to amniotic fluid AFP superior to serum levels as a predictor of pregnancy complications? Arch Gynecol Obstet. 2016;293:767\u201370.2645336110.1007\/s00404-015-3905-9","DOI":"10.1007\/s00404-015-3905-9"},{"key":"2023040100153360800_j_jpm-2016-0101_ref_027_w2aab3b7b2b1b6b1ab1b5c27Aa","doi-asserted-by":"crossref","unstructured":"Dugoff L; Society for Maternal-Fetal Medicine. First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. Obstet Gynecol. 2010;115:1052\u201361.10.1097\/AOG.0b013e3181da93da20410782","DOI":"10.1097\/AOG.0b013e3181da93da"}],"container-title":["Journal of Perinatal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jpme.2017.45.issue-7\/jpm-2016-0101\/jpm-2016-0101.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2016-0101\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2016-0101\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T14:35:22Z","timestamp":1680359722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2016-0101\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,24]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,4,13]]},"published-print":{"date-parts":[[2017,10,26]]}},"alternative-id":["10.1515\/jpm-2016-0101"],"URL":"https:\/\/doi.org\/10.1515\/jpm-2016-0101","relation":{},"ISSN":["1619-3997","0300-5577"],"issn-type":[{"value":"1619-3997","type":"electronic"},{"value":"0300-5577","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10,24]]}}}